Affimed (NASDAQ:AFMD) Earns Buy Rating from HC Wainwright

Affimed (NASDAQ:AFMD)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $10.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s target price indicates a potential upside of 342.48% from the stock’s previous close.

AFMD has been the topic of several other reports. Stifel Nicolaus decreased their price objective on shares of Affimed from $5.00 to $4.00 and set a “hold” rating on the stock in a research report on Friday, November 15th. Cantor Fitzgerald reissued an “overweight” rating on shares of Affimed in a report on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, Affimed currently has an average rating of “Moderate Buy” and an average target price of $16.00.

Affimed Trading Down 2.6 %

NASDAQ:AFMD opened at $2.26 on Tuesday. Affimed has a 52-week low of $2.18 and a 52-week high of $8.95. The stock has a fifty day moving average of $3.13 and a 200 day moving average of $4.20. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.93 and a quick ratio of 1.93.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of AFMD. Jane Street Group LLC purchased a new stake in shares of Affimed in the 3rd quarter valued at $44,000. Choreo LLC purchased a new position in Affimed in the 2nd quarter worth $54,000. FMR LLC lifted its stake in Affimed by 30.0% in the third quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after purchasing an additional 4,086 shares during the last quarter. Intellectus Partners LLC boosted its position in Affimed by 12.2% during the third quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock valued at $317,000 after buying an additional 10,250 shares during the period. Finally, Point72 Asset Management L.P. grew its stake in shares of Affimed by 4.6% during the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after buying an additional 15,108 shares during the last quarter. 30.82% of the stock is currently owned by institutional investors.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.